视网膜静脉阻塞是目前一种常见的视网膜血管疾病,其继发的黄斑水肿是导致视力下降的最主要的原因。血管内皮生长因子(VEGF)在视网膜静脉阻塞继发黄斑水肿的发病中起重要作用。目前临床上以玻璃体腔内注射抗VEGF抗体Bevacizumab来治疗多种眼部新生血管性及渗出性疾病,但其对视网膜静脉阻塞继发黄斑水肿治疗的长期效果及安全性尚有待多中心研究进一步证实。作者就这方面的研究进展作一综述。

[1] MRUTHYUNJAYA P,FEKRAT S.Central retinal vein occlusion[M]//RYAN S J.Retina.4th.St.Louis:Mosby,2006:1339-1348.
[2] MCLNTOSH R L,ROGERS S L,LIM L,et al.Natural history of central retinal vein occlusion:an evidence-based systematic review[J].Ophthalmology,2010,117:1113-1123.
[3] GREER D V,CONSTABLE I J,COOPER R L.Macular oedema and retinal branch vein occlusion[J].Aust J Ophthalmol,1980,8(3):207-209.
[4] 惠延年.视网膜静脉阻塞的治疗趋势[J].眼科,2010,19(4):221-223.
[5] PHILLIPS S,FEKRAT S,FINKELSTEIN D.Branch retinal vein occlusion[M]// RYAN S J.Retina.4th ed.St.Louis:Mosby,2006:1349-1354.
[6] ROGERS S L,MCLNTOSH R L,LIM L,et al.Natural history of branch retinal vein occlusion:an evidence-based systematic review[J].Ophthalmology,2010,117:1094-1101.
[7] FERRARA N.Vascular endothelial growth factor:basic science and clinical Progress[J].Endocr Rev,2004,25:581-611.
[8] The Center Vein Occlusion Study Group.A randomized clinical trail of early panretinal photocoagulation for ischemic central retinal vein occlusion:the CVOS Group N report[J].Ophthalmology,1995,102(10):1434-1444.
[9] [No authors listed].Argon laser photocoagulation for macular edema in branch vein occlusion.The Branch Vein Occlusion Study Group[J].Am J Ophthalmol,1984,98(3):271-282.
[10] SCOTT I U,IP M S,Van VELDHUISEN P C,et al.A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion:the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6[J].Arch Ophthalmol,2009,127(9):1115-1128.
[11] 张永鹏,彭晓燕.视网膜中央静脉阻塞继发黄斑水肿的治疗进展—从临床试验到临床实践[J].眼科,2012,21(4):222-227.
[12] STAHL A,AGOSTINI H,HANSEN L L,et al.Bevacizumab in retinal vein occlusion-resultsof a prospective case series[J].Graefes Arch Clin Exp Ophthalmol,2007,245(10):1429-1436.
[13] BROWN D M,CAMPOEHIARO P A,SINGH R P,et al.Ranibizumab for macular edema following central retinal vein occlusion six-month primary end point results of a Phase III study[J].Ophthalmology,2010,117(6):1124-1133.
[14] 沈宵,常青.视网膜静脉阻塞抗血管内皮生长因子治疗研究进展[J].中华眼底病杂志,2013,29(6).634-637.
[15] EPSTEIN D L,ALGVERE P V,Von WENDT G,et al.Benefit from Bevacizumab for macular edema in central retinal vein occlusion:twelve-month results of a prospcctive.randomized study[J].Ophthalmology,2012,119:2587-2591.
[16] ROH M I,BYEON S H,KWON O W.Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema[J].Retina,2008,28(9):1314-1318.
[17] ZIEMSSEN F,DEUTER C M,STUEBIGER N,et al.Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab(Avastin)[J].Graefes Arch Clin Exp Ophthalmol,2007,245(6):917-918.
[18] WU L,AREVALDO J F,ROCA J A,et al.Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion:results from the Pan-American Collaborative Retina Study Group at 6 months of Follow-Up[J].Retina,2008,28:212-219.
[19] 孙晓东,宫媛媛,汪枫桦.慎重应用抗新生血管药物治疗视网膜静脉阻塞继发的黄斑水肿[J].中华眼底病杂志2010,46(2):100-102.